Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 7/20 | 0.56 |
| ▸ | CTSK | P43235 | 6/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | PPARG | P37231 | 2/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | PTPRB | P23467 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3825012 | 0.88 | ATM (0.55) | CTSSCTSKGAAMEN1KMT2A | |
| SCHEMBL1186455 | 0.88 | ATM (0.55) | CTSSCTSKGAAMEN1KMT2A | |
| SCHEMBL825959 | 0.88 | ATM (0.55) | CTSSCTSKGAAMEN1KMT2A | |
| SCHEMBL2799300 | 0.87 | GAA (0.50) | CTSSCTSKGAAMEN1KMT2A | |
| SCHEMBL3697318 | 0.87 | CTSS (0.56) | CTSSCTSKGAAMEN1KMT2A | |
| SCHEMBL2799041 | 0.87 | GAA (0.50) | CTSSCTSKGAAMEN1KMT2A | |
| SCHEMBL12101475 | 0.87 | MEN1 (0.47) | CTSSCTSKGAAMEN1KMT2A | |
| SCHEMBL16798417 | 0.86 | LDHA (0.52) | GAAMEN1KMT2ASYKEPHX2 | |
| SCHEMBL30718545 | 0.84 | CYP17A1 (0.47) | CTSSCTSKGAAMEN1KMT2A | |
| SCHEMBL2263968 | 0.83 | GAA (0.41) | CTSSCTSKGAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11376260-B2 | Serine/threonine kinase inhibitors | GENENTECH, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| US-20210106593-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2021-04-15 | — | — | US | disclosed |
| US-10842799-B2 | Serine/threonine kinase inhibitors | GENENTECH, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| US-20200078371-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2020-03-12 | — | — | US | disclosed |
| US-20190192534-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2019-06-27 | — | — | US | disclosed |
| US-10278975-B2 | Serine/threonine kinase inhibitors | GENENTECH, INC. (US) | 2019-05-07 | — | — | US | disclosed |
| CN-106029672-B | serine/threonine kinase inhibitors | 基因泰克公司 | 2019-03-29 | — | — | CN | disclosed |
| EP-3077401-B1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH INC (US) | 2018-04-18 | — | — | EP | disclosed |
| US-9867833-B2 | Serine/threonine kinase inhibitors | GENENTECH, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-20180000833-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2018-01-04 | — | — | US | disclosed |
| EP-3077401-A1 | SERINE/THREONINE KINASE INHIBITORS | Genentech, Inc. (US) | 2016-10-12 | — | — | EP | disclosed |
| CN-106029672-A | Serine/threonine kinase inhibitors | 基因泰克公司 | 2016-10-12 | — | — | CN | disclosed |
| US-20150182537-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2015-07-02 | — | — | US | disclosed |
| WO-2015085007-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2015-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11376260-B2 | Serine/threonine kinase inhibitors | MAP3K1, MAP3K4, MAP4K2 | CTSS 4008/4885CTSK 2774/4885GAA 3060/4885 |
| US-10842799-B2 | Serine/threonine kinase inhibitors | MAP3K1, MAP3K4, MAP4K2 | CTSS 4008/4885CTSK 2774/4885GAA 3060/4885 |
| US-20150182537-A1 | SERINE/THREONINE KINASE INHIBITORS | MAP3K1, MAP3K4, MAP4K2 | CTSS 4008/4885CTSK 2774/4885GAA 3060/4885 |
| US-20180000833-A1 | SERINE/THREONINE KINASE INHIBITORS | MAP3K1, MAP3K4, MAP4K2 | CTSS 4008/4885CTSK 2774/4885GAA 3060/4885 |
| US-10278975-B2 | Serine/threonine kinase inhibitors | MAP3K1, MAP3K4, MAP4K2 | CTSS 4008/4885CTSK 2774/4885GAA 3060/4885 |
| US-20190192534-A1 | SERINE/THREONINE KINASE INHIBITORS | MAP3K1, MAP3K4, MAP4K2 | CTSS 4008/4885CTSK 2774/4885GAA 3060/4885 |
| US-20210106593-A1 | SERINE/THREONINE KINASE INHIBITORS | MAP3K1, MAP3K4, MAP4K2 | CTSS 4008/4885CTSK 2774/4885GAA 3060/4885 |
| US-20200078371-A1 | SERINE/THREONINE KINASE INHIBITORS | MAP3K1, MAP3K4, MAP4K2 | CTSS 4008/4885CTSK 2774/4885GAA 3060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.